Redeye views the completed analytical validation as a confirmation that the development of the DiviTum cancer diagnostic test is on track, with sights on a potential FDA clearance in the beginning of next year. We increase likelihood of approval. Also, we have reviewed our cost forecasts taking a more positive stance on margins in a partnering structure. We raise our base case to SEK 31 (24).